Ultragenyx Pharmaceutical (RARE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Ultragenyx Pharmaceutical (RARE) is Neutral.

The composite score behind that read is -0.06, weighing +0.24 of bullish evidence against -0.36 bearish.

Ultragenyx Pharmaceutical last closed at $15.48, +1.24% on the session.

Against the IVW growth benchmark the position is +0.44% over the forecast window.

The read is built from 15 underlying insights — 7 bullish and 8 bearish.

Agreement across those insights is 53%.

3 graded predictions for RARE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Ultragenyx Pharmaceutical in the 98th percentile on return on equity, where 100 is best.

Ultragenyx Pharmaceutical is classified under Health Care / Biotechnology, with a market capitalisation of $1.51B.

StockMap tracks Ultragenyx Pharmaceutical as the 111th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Ultragenyx Pharmaceutical ranks 173rd of 381 in the group, against a group median of -0.08.